This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Needham Adjusts iRhythm Technologies' PT to $138 From $137, Says 'Strong' Q1 Revenue Growth Should Continue; Keeps Buy Rating MT
Transcript : IRhythm Technologies, Inc., Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (IRTC) IRHYTHM Posts Q1 Revenue $131.9M, vs. Street Est of $128.4M MT
IRhythm Technologies, Inc. Revises Earnings Guidance for the Year 2024 CI
IRhythm Technologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
IRhythm Technologies Closes $661 Million Notes Offering MT
Irhythm Technologies Insider Sold Shares Worth $360,983, According to a Recent SEC Filing MT
IRhythm Technologies Prices $575 Million Convertible Notes Offering MT
IRhythm Shares Fall After Firm Plans $450 Million Convertible Notes Offering MT
IRhythm Technologies Plans to Offer $450 in Convertible Notes Due 2029 MT
Needham Adjusts iRhythm Technologies' Price Target to $137 From $136, Keeps Buy Rating MT
IRhythm Technologies Q4 Adjusted Loss Widens, Revenue Rises; 2024 Sales Outlook Set -- Shares Slump After Hours MT
Transcript : IRhythm Technologies, Inc., Q4 2023 Earnings Call, Feb 22, 2024
IRhythm Technologies, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
IRhythm Technologies, Inc. Provides Earnings Guidance for the Year 2024 CI
IRhythm Technologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : IRhythm Technologies, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 04:30 PM
IRhythm Technologies Closes $150 Million Debt Facility; 2024 Revenue Forecast Issued MT
Needham Raises iRhythm Technologies' Price Target to $136 From $108, Keeps Buy Rating MT
Irhythm Technologies, Inc. Entered into A Credit, Security and Guaranty Agreement with Braidwell Transaction Holdings LLC CI
IRhythm Technologies, Inc. Revises Revenue Guidance for the Year 2024 CI
IRhythm Technologies Says Study Shows Zio Has 'Higher Diagnostic Yield' Compared With Other Cardiac Monitors MT
IRhythm , Inc. Announces Results from the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events CI
Irhythm Technologies Insider Sold Shares Worth $745,692, According to a Recent SEC Filing MT
IRhythm Technologies Says it Obtained EU CE Mark for Zio Monitor, Zeus System MT
Chart iRhythm Technologies, Inc.
More charts
iRhythm Technologies, Inc. is a digital health care company, which creates solutions that detect, predict, and prevent disease. The Company designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. It offers three Zio System options: the Zio Monitor System, the Zio XT System, and the Zio AT System. It offers its Zio ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry monitoring services (Zio Services), using its Zio Systems. The Zio Monitor System is a prescription-only, remote ECG monitoring system that consists of a patch ECG monitor (the Zio Monitor patch) that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
110.9 USD
Average target price
138.5 USD
Spread / Average Target
+24.91%
Consensus
  1. Stock Market
  2. Equities
  3. IRTC Stock
  4. News iRhythm Technologies, Inc.
  5. iRhythm Technologies : BTIG Downgrades IRhythm Technologies to Neutral From Buy